Scientific Sessions 2024  /  Gene Therapy in the Cardiology Clinic: Ready for Prime Time?  /  Gene Therapy in 2024: What Are the Options?
Logo

American Heart Association

  2
  0

Final ID:

Gene Therapy in 2024: What Are the Options?

  • Helms, Adam  ( UNIVERSITY OF MICHIGAN , Ann Arbor , Michigan , United States )
  • Rosanno, Joseph  ( Children's Hospital of Philadelphia , Philadelphia , Pennsylvania , United States )
  • Giacca, Mauro  ( King's College London , London , United Kingdom )
    • Author Disclosures:
    Adam Helms: DO have relevant financial relationships ; Consultant:Tenaya Therapeutics:Active (exists now) ; Consultant:Bristol Myers Squibb:Active (exists now) ; Consultant:Lexeo Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Tenaya Therapeutics:Active (exists now) | Joseph Rosanno: No Answer | Mauro Giacca: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Gene Therapy in the Cardiology Clinic: Ready for Prime Time?

Monday, 11/18/2024 , 01:30PM - 02:45PM

Main Event

More abstracts on this topic:
Gene Silencing: Targeting TTR in Amyloidosis as a Paradigm for Knocking Down Mutant Alleles

Alexander Kevin, Garcia-pavia Pablo

Gene Therapy for Lysosomal Storage Disorders: From the Bench to the Bedside

Adler Eric, Greenberg Barry

More abstracts from these authors:
Noncoding regulation of epicardial gene expression and epithelial-to-mesenchymal transition during heart development

Nunes Vieira Joaquim, Roque Silva Carolina, Valenzuela Sanchez Mariana, Scheucher Hannah, Dias Tiago, Kalisch-smith Jacinta, Sparrow Duncan, Giacca Mauro, Riley Paul

Cardioactive molecules identified by functional in vivo screening prevent anthracycline cardiotoxicity

Bortolotti Francesca, Mura Antonio, Riccio Matteo Maria, Dal Ferro Matteo, Zentilin Lorena, Giacca Mauro

You have to be authorized to contact abstract author. Please, Login
Not Available